PUBLICATIONS

 Granieri L, Miller OJ, Griffiths AD, Merten CA. A competition-based assay for the screening of species-specific antibiotics. 2009. J. Antimicrob. Chem. 64(1): 62-68.

 Pianowski Z, Gorska Z, Oswald L, Merten CA, Winssinger N. Imaging of mRNA in Live Cells Using Nucleic Acid-Templated Reduction of Azidorhodamine Probes. 2009. JACS 131(18): 6492-6497.

 Baret JC, Taly V, Ryckelynck M, Merten CA, Griffiths AD. Droplets and Emulsions: Very High-Throughput Screening in Biology. 2009. Medecine Science (french) 25: 627-632.

 Köster S, Angilè FE, Duan H, Agresti JJ, Wintner A, Schmitz C, Rowat AC, Merten CA, Pisignano D, Griffiths AD, Weitz DA. Drop-based microfluidic devices for encapsulation of single cells. 2008. Lab Chip. 8(7): 1110-1115.

 Clausell-Tormos J, Lieber D, Baret J-C, El Harrak A, Miller OJ, Blouwolff J, Humphry KJ, Koster S, Duan H, Holtze C, Weitz DA, Griffiths DA & Merten CA. Droplet-based microfluidic platforms for the encapsulation and screening of mammalian cells and multicellular organisms. 2008. Chemistry and Biology. 15: 427–437.
(Research Highlight in Nature Methods 5(7): 580-581. 2008.)

 Merten CA, Stitz J, Braun G, Medvedovska J, Cichutek K & Buchholz CJ. Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein. 2006. Nucleic Acids Res. 34(5):e41.

 Merten CA. Directed Evolution of Tissue Plasminogen Activator towards Increased Fibrin Specificity and Decreased Sensibility to Plasminogen Activator Inhibitor by In Vitro Compartmentalization. 2006. Nova Acta LeopoldinaS20:107-108.

 Nikles D, Bach P, Boller K, Merten CA, Montrasio F, Heppner FL, Aguzzi A, Cichutek K, Kalinke U & Buchholz CJ. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. 2005. J Virol.79(7):4033-4042.

 Merten CA, Stitz J, Braun G, Poeschla EM, Cichutek K & Buchholz CJ. Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. 2005. J Virol. 79(2):834-840.

 Merten CA, Engelstaedter M, Buchholz CJ & Cichutek K. Displaying epidermal growth factor on spleen necrosis virus-derived targeting vectors. 2003. Virology. 305(1):106-14.

PATENTS

 P034754GB 0822261.4. (2008). Assay (resistance to viral cell-entry). Merten CA. Applicant: Medical Research Council, UK

 P034748GB 0822260.6. (2008). Assay (growth of bacteria and cancer cells). Merten CA. Applicant: Medical Research Council, UK

 US provisional patent US12/172,186. (2008). Droplet-Based Selection. Weitz DA, Griffiths AD, Koester S, Mootha V, Duan H, Agresti JJ, Merten CA, , Heyman J, Gilbert J. Applicant: Harvard University, Cambridge, USA

 US provisional patent US60/937,978. (2007). Microfluidic system for the encapsulation of living cells and multicellular organisms. Merten CA., Applicant: Christoph Merten, supported by Université Louis Pasteur, Strasbourg, France

PTC/GB2006/000316. (2006) Screening method. Merten CA., Applicant: Medical Research Council, London, UK (based on the formerly filed US provisional patent 60/648,827).